Is BHRT safe? What do doctors say about bioidentical hormones?

Short answer: Bioidentical hormone therapy (BHRT) can be safe and effective for many people when it uses FDA‑approved products and is prescribed and monitored by a qualified clinician. “Compounded” bioidentical hormones — custom‑made by compounding pharmacies and marketed as natural or safer — carry additional uncertainty and risk, and most major medical societies advise caution or recommend using FDA‑approved preparations instead.

What “bioidentical” means

• “Bioidentical” refers to hormones that are chemically identical to the hormones your body makes (for example, 17β‑estradiol or micronized progesterone).
• Some FDA‑approved commercial products are bioidentical (they contain estradiol or micronized progesterone). Other products labeled “bioidentical” are compounded mixtures that are not FDA‑approved.

What doctors and major organizations say

• North American Menopause Society (NAMS), American College of Obstetricians and Gynecologists (ACOG), Endocrine Society and the FDA all say: hormone therapy can be an appropriate treatment for menopausal symptoms and some health conditions, but use should be individualized and evidence‑based.
• These organizations caution against routine use of compounded (non‑FDA) bioidentical hormones because they may lack consistent dosing, purity testing, standardized labeling and safety/efficacy data.
• The FDA has issued warnings about compounded bioidentical hormone products and about clinics that promote saliva testing and custom dosing schemes without evidence.

What the evidence says about risks and benefits

• Benefits: Hormone therapy (HT) is the most effective treatment for vasomotor symptoms (hot flashes) and vaginal dryness. HT can also help prevent bone loss.
• Risks: The Women’s Health Initiative and subsequent analyses showed increased risks in some women (depend on formulation, dose, duration, and timing). Potential risks include venous thromboembolism (blood clots), stroke, and — with some combined regimens — an increase in breast cancer risk over time. The magnitude of those risks depends on the type of estrogen, whether a progestogen is used, the route (oral vs transdermal), patient age and time since menopause.
• Important nuances:
  • “Timing”: initiating HT near the time of menopause (generally within 10 years) seems to have a more favorable risk/benefit balance for many women than starting it much later.
  • Route matters: transdermal estradiol (patch or gel) is associated with a lower risk of blood clots than oral estrogen in many studies.
  • Progestogen choice matters: micronized progesterone (Prometrium) may have a different safety profile than synthetic progestins for some outcomes.
  • Compounded products: lack rigorous studies proving they’re safer or more effective; dose inconsistency has been documented.

Practical recommendations doctors commonly give

• Prefer FDA‑approved bioidentical formulations when possible rather than compounded custom mixtures. Examples:
  • Transdermal estradiol patches: Vivelle‑Dot, Climara (good option for systemic estrogen, lower clot risk).
  • Oral estradiol: Estrace (for systemic estrogen).
  • Micronized progesterone: Prometrium (to protect the uterus when estrogen is given to women with a uterus).
  • Progestin IUD: Mirena (effective uterine protection with fewer systemic progestin effects for some women).
• Use the lowest effective dose for the shortest duration needed for your treatment goals, reassessing regularly.
• Avoid relying on saliva testing or other nonstandard hormone assays for dosing decisions — these are not supported by mainstream medical organizations.

Questions to ask your clinician

• Is an FDA‑approved bioidentical product an option for me?
• What are the risks for me given my age, family history, heart disease/stroke risk, clotting history, breast cancer history?
• Should I use transdermal estrogen or oral? Do I need progesterone or an IUD?
• How will you monitor benefits and side effects, and how often will we reassess treatment?
• If someone recommends compounded BHRT, why is that preferred over an FDA‑approved product?

When to avoid or use caution

• Active or recent breast cancer, known or suspected estrogen‑sensitive cancer, history of unprovoked venous thromboembolism, active liver disease, or certain cardiovascular conditions — these require individualized evaluation and often favor avoiding systemic estrogen or using alternatives.

Bottom line

• “Bioidentical” per se is not inherently safer or more dangerous; safety depends on the specific product, dose, route, timing and the patient’s medical profile. Most doctors and professional societies recommend FDA‑approved bioidentical hormones (examples above) over compounded products, careful individualized prescribing, and regular follow‑up.

If you want, tell me your sex, age, menopausal status, major medical history (especially clotting, heart disease, breast cancer), and what symptoms you want to treat — I can outline options and specific things to discuss with your clinician.